Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 7/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 7/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 7/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26808381 | 0.83 | HTR1A (0.41) | USP1PDE1APDE1BPDE1CTRPC5 | |
| SCHEMBL29566529 | 0.83 | HTR1A (0.41) | USP1PDE1APDE1BPDE1CTRPC5 | |
| SCHEMBL24310671 | 0.82 | JAK2 (0.36) | USP1PDE1APDE1BPDE1CTRPC5 | |
| SCHEMBL24309663 | 0.82 | GPR39 (0.37) | JAK1JAK3 | |
| SCHEMBL24309850 | 0.78 | AXL (0.35) | USP1JAK1JAK3 | |
| SCHEMBL24309763 | 0.78 | USP1 (0.33) | USP1JAK1JAK3 | |
| SCHEMBL24309345 | 0.75 | JAK1 (0.32) | USP1JAK1JAK3 | |
| SCHEMBL24310657 | 0.75 | AXL (0.31) | USP1JAK1JAK3 | |
| SCHEMBL24309346 | 0.75 | — | — | |
| SCHEMBL29566840 | 0.71 | F2 (0.34) | USP1NUDT1TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |